AlJazira Capital issues Q4 2025 profit forecastsArgaam Special15/01/2026
SNB Capital sets Q4 2025 earnings estimatesArgaam Special14/01/2026
GIB Capital previews Q4 2025 earnings Argaam13/01/2026
Key events to drive Saudi-listed firms' performance in Q4 2025Argaam Special18/01/2026
Analyst preview for Avalon Pharma's Q3 2025 earningsArgaam Special04/11/2025
In-depth: Performance of recently-listed TASI firms, key offering indicators since 2024Argaam Special21/09/2025
Q1 2025 earnings: What to expect for Avalon PharmaArgaam Special07/05/2025
What you need to know ahead of Avalon Pharma Q4 2024 earnings reportArgaam Special18/02/2025
Market Data
| Last Trade | 113.80 |
| Change | 0.20 |
| Change (%) | 0.18 |
| Open | 113.20 |
| Low | 113.00 |
| High | 114.30 |
| Prev. Close | 113.60 |
| Change (3M) | (8.30 %) |
| Change (6M) | (5.95 %) |
| Volume | 18,325 |
| Turnover | 2,086,054.00 |
| Transactions | 418 |
| Market Value | 2,276.00 |
| Avg. Volume (3M) | 39,459.33 |
| Avg. Turnover (3M) | 4,571,930.88 |
| Avg. Transaction (3M) | 694.27 |
| Change (12M) | (15.07 %) |
| YTD | 2.34 % |
|
Event Date
|
Event
|
||
|---|---|---|---|
|
15-09-2025
|
Cash Dividend Distribution | ||
|
01-09-2025
|
Ex-dividend Date | ||
|
29-05-2025
|
General Assembly | ||
|
15-05-2025
|
Cash Dividend Distribution | ||
|
01-05-2025
|
Ex-dividend Date | ||
| More | |||
| Date | Research firm | Rating |
|
|
AlJazira Capital | Overweight |
|
|
Al Rajhi Capital | Neutral |
|
|
AlJazira Capital | Neutral |
|
|
GIB Capital | Overweight |
Call Request